Veradigm EBITDA Margin 2010-2022 | MDRX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Veradigm (MDRX) over the last 10 years. The current EBITDA margin for Veradigm as of December 31, 2022 is .
| Veradigm EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2022-12-31 | $0.59B | $0.09B | 15.11% |
| 2022-09-30 | $0.60B | $0.13B | 20.86% |
| 2022-06-30 | $0.60B | $0.12B | 20.44% |
| 2022-03-31 | $0.59B | $0.15B | 25.04% |
| 2021-12-31 | $0.58B | $0.15B | 25.95% |
| 2021-09-30 | $-0.14B | $0.11B | -75.00% |
| 2021-06-30 | $0.08B | $0.11B | 130.86% |
| 2021-03-31 | $0.31B | $0.09B | 29.77% |
| 2020-12-31 | $0.56B | $0.10B | 17.27% |
| 2020-09-30 | $1.43B | $0.00B | 0.21% |
| 2020-06-30 | $1.51B | $0.03B | 1.86% |
| 2020-03-31 | $1.58B | $0.07B | 4.36% |
| 2019-12-31 | $1.63B | $0.10B | 6.07% |
| 2019-09-30 | $1.63B | $0.13B | 8.16% |
| 2019-06-30 | $1.62B | $0.12B | 7.42% |
| 2019-03-31 | $1.62B | $0.05B | 2.85% |
| 2018-12-31 | $1.62B | $0.03B | 1.79% |
| 2018-09-30 | $1.52B | $0.03B | 2.18% |
| 2018-06-30 | $1.53B | $0.06B | 4.17% |
| 2018-03-31 | $1.52B | $0.15B | 9.88% |
| 2017-12-31 | $1.50B | $0.17B | 11.36% |
| 2017-09-30 | $1.55B | $0.25B | 16.06% |
| 2017-06-30 | $1.49B | $0.23B | 15.47% |
| 2017-03-31 | $1.45B | $0.22B | 15.06% |
| 2016-12-31 | $1.39B | $0.20B | 14.71% |
| 2016-09-30 | $1.47B | $0.23B | 15.50% |
| 2016-06-30 | $1.43B | $0.22B | 15.14% |
| 2016-03-31 | $1.40B | $0.20B | 14.52% |
| 2015-12-31 | $1.39B | $0.19B | 13.91% |
| 2015-09-30 | $1.38B | $0.18B | 12.74% |
| 2015-06-30 | $1.37B | $0.15B | 10.92% |
| 2015-03-31 | $1.37B | $0.14B | 10.06% |
| 2014-12-31 | $1.38B | $0.14B | 9.80% |
| 2014-09-30 | $1.39B | $0.11B | 8.00% |
| 2014-06-30 | $1.37B | $0.09B | 6.56% |
| 2014-03-31 | $1.37B | $0.07B | 5.12% |
| 2013-12-31 | $1.37B | $0.05B | 3.71% |
| 2013-09-30 | $1.37B | $0.05B | 3.28% |
| 2013-06-30 | $1.40B | $0.09B | 6.34% |
| 2013-03-31 | $1.43B | $0.13B | 9.03% |
| 2012-12-31 | $1.45B | $0.16B | 11.26% |
| 2012-09-30 | $1.48B | $0.23B | 15.57% |
| 2012-06-30 | $1.49B | $0.25B | 16.95% |
| 2012-03-31 | $1.47B | $0.26B | 17.77% |
| 2011-12-31 | $1.44B | $0.27B | 18.63% |
| 2011-09-30 | $1.37B | $0.21B | 15.38% |
| 2011-06-30 | $1.25B | $0.16B | 12.72% |
| 2011-03-31 | $1.08B | $0.12B | 11.44% |
| 2010-09-30 | $0.62B | $0.09B | 14.10% |
| 2010-06-30 | $0.56B | $0.11B | 20.18% |
| 2010-03-31 | $0.53B | $0.12B | 23.08% |
| 2010-02-28 | $0.51B | $0.10B | 20.23% |
| 2009-09-30 | $0.49B | $0.08B | 16.50% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.531B | $0.588B |
| Veradigm Inc. is a healthcare technology company which drives value through its combination of platforms, data, expertise, connectivity and scale. Its network features a dynamic community of solutions and partners providing advanced insights, technology and data-driven solutions. Veradigm Inc., formerly known as Allscripts Healthcare Solutions Inc., is based in CHICAGO. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $46.412B | 59.05 |
| Tempus AI (TEM) | United States | $12.731B | 0.00 |
| Doximity (DOCS) | United States | $12.055B | 53.63 |
| Hims & Hers Health (HIMS) | United States | $9.805B | 80.33 |
| IRhythm Technologies (IRTC) | United States | $5.243B | 0.00 |
| Hinge Health (HNGE) | United States | $4.466B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.752B | 40.46 |
| Privia Health (PRVA) | United States | $2.596B | 192.27 |
| Heartflow (HTFL) | $2.379B | 0.00 | |
| Enovis (ENOV) | United States | $1.715B | 9.06 |
| 10x Genomics (TXG) | United States | $1.663B | 0.00 |
| Phreesia (PHR) | United States | $1.648B | 0.00 |
| Omnicell (OMCL) | United States | $1.458B | 28.10 |
| Schrodinger (SDGR) | United States | $1.425B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.302B | 0.00 |
| Claritev (CTEV) | United States | $1.088B | 0.00 |
| Evolent Health (EVH) | United States | $1.052B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.654B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.568B | 0.00 |
| Standard BioTools (LAB) | United States | $0.470B | 0.00 |
| Talkspace (TALK) | United States | $0.430B | 128.50 |
| Butterfly Network (BFLY) | United States | $0.355B | 0.00 |
| Carlsmed (CARL) | United States | $0.320B | 0.00 |
| TruBridge (TBRG) | United States | $0.291B | 51.03 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.242B | 0.00 |
| Outset Medical (OM) | United States | $0.237B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.216B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.205B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.192B | 0.00 |
| CapsoVision (CV) | United States | $0.184B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.139B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.133B | 0.00 |
| CareCloud (CCLD) | United States | $0.112B | 5.08 |
| American Well (AMWL) | United States | $0.111B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.077B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.072B | 0.00 |
| 111 (YI) | China | $0.063B | 0.00 |
| Pulmonx (LUNG) | United States | $0.062B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.053B | 0.00 |
| HeartBeam (BEAT) | United States | $0.039B | 0.00 |
| Precipio (PRPO) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.022B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.012B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| HeartSciences (HSCS) | United States | $0.009B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Movano (MOVE) | United States | $0.004B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.004B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| PROFUSA (PFSA) | United States | $0.003B | 0.00 |